Clinical Trials

RTL1000 Clinical Protocol

A double-blind, placebo-controlled, Phase 1, Dose escalation Study of the Safety of A Single Dose of RTL1000 in MS Patients

Primary Objective:

Evaluate the safety profile of a single intravenous (IV) dose of RTL1000 (Clinical exam and MRI)

Five cohorts (escalating doses ranging from 2mg to 200mg)

• Six subjects/cohort (4 drug; 2 placebo)
• All subjects will be followed over 28 days

Clinical Sites:

• University of Maryland, College Park
• OHSU, Portland
• Kansas University, Kansas City
• Indiana University, Indianapolis
• Yale, New Haven
• Seattle Evergreen

Links

RTL1000 Safety Study at Clinical Trials.gov